This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Recent advances in human genetics, together with a large body of epidemiologic,
preclinical, and clinical trial results, provide strong support for a causal association between …

Rare diseases, an emerging global public health priority, require an evidence-based
estimate of the global point prevalence to inform public policy. We used the publicly …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Background: Contemporary studies suggest that familial hypercholesterolemia (FH) is more
frequent than previously reported and increasingly recognized as affecting individuals of all …

Background Familial hypercholesterolemia is characterized by an elevated level of low-
density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic …

Lipid nanoparticles have demonstrated utility in hepatic delivery of a range of therapeutic
modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated …

Background Homozygous familial hypercholesterolemia is characterized by premature
cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) …

Summary Background Homozygous familial hypercholesterolaemia (HoFH) is a rare
inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels …